A Phase 1, Open-Label Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2016
Price : $35 *
At a glance
- Drugs Cobimetinib (Primary) ; Itraconazole
- Indications Malignant melanoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Genentech
- 04 Sep 2013 Planned End Date changed from 1 May 2015 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 02 Sep 2013 New trial record
- 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.